S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
NASDAQ:INO

Inovio Pharmaceuticals News Headlines

$6.10
-0.07 (-1.13%)
(As of 12/6/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.75
$6.12
50-Day Range
$6.10
$7.77
52-Week Range
$5.74
$19.00
Volume
5.90 million shs
Average Volume
8.04 million shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.58

Media Mentions By Week



Inovio Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INO
News Sentiment

-0.08

0.34

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INO Articles
This Week

6

5

INO Articles
Average Week

Get Inovio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Inovio Pharmaceuticals (NASDAQ:INO) News Headlines Today

SourceHeadline
MarketBeat logoInovio Pharmaceuticals (NASDAQ:INO) Hits New 1-Year Low at $5.75
americanbankingnews.com - December 6 at 10:51 AM
finance.yahoo.com logoIs Inovio Stock Set to Rebound?
finance.yahoo.com - December 2 at 9:49 AM
markets.businessinsider.com logoINOVIO To Test Its COVID-19 Vaccine Candidates Against Omicron Variant - Quick Facts
markets.businessinsider.com - November 30 at 9:42 AM
finance.yahoo.com logoINOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
finance.yahoo.com - November 30 at 9:42 AM
finance.yahoo.com logoUPDATE 1-Novavax developing vaccine that targets new COVID-19 variant
finance.yahoo.com - November 26 at 7:42 PM
MarketBeat logoInovio Pharmaceuticals (NASDAQ:INO) Shares Gap Up to $6.92
americanbankingnews.com - November 26 at 11:10 AM
marketwatch.com logoGlobal Zika Virus Vaccine Market Research Report: Know Market Dynamics, Opportunities and Risks Assessment from 2022 to 2026
marketwatch.com - November 26 at 9:41 AM
MarketBeat logoAnalyzing Inovio Pharmaceuticals (NASDAQ:INO) and 3M (NYSE:MMM)
americanbankingnews.com - November 24 at 8:03 AM
MarketBeat logoInovio Pharmaceuticals (NASDAQ:INO) & 3M (NYSE:MMM) Head-To-Head Contrast
americanbankingnews.com - November 17 at 9:25 AM
finance.yahoo.com logoDoes This News Make Inovio Pharmaceuticals Stock a Buy?
finance.yahoo.com - November 17 at 8:46 AM
MarketBeat logoEquities Analysts Issue Forecasts for Inovio Pharmaceuticals, Inc.'s FY2021 Earnings (NASDAQ:INO)
americanbankingnews.com - November 15 at 1:58 AM
MarketBeat logoInovio Pharmaceuticals (NASDAQ:INO) versus Aethlon Medical (NASDAQ:AEMD) Head-To-Head Survey
americanbankingnews.com - November 13 at 1:16 AM
finance.yahoo.com logoInovio Stock at $35 a Share? This Analyst Thinks It’s Possible
finance.yahoo.com - November 12 at 10:59 PM
MarketBeat logoInovio Pharmaceuticals (NASDAQ:INO) Issues Earnings Results
americanbankingnews.com - November 12 at 5:44 PM
MarketBeat logoInovio Pharmaceuticals, Inc. (NASDAQ:INO) to Post FY2021 Earnings of ($1.28) Per Share, Piper Sandler Forecasts
americanbankingnews.com - November 12 at 8:26 AM
marketwatch.com logoInovio Pharmaceuticals Inc. stock rises Thursday, outperforms market
marketwatch.com - November 12 at 1:43 AM
finance.yahoo.com logoFDA Gives Inovio Pharmaceuticals the All-Clear to Continue Phase 3 Covid Segment
finance.yahoo.com - November 11 at 9:30 AM
finance.yahoo.com logoWhy Inovio Stock Is Rising Today
finance.yahoo.com - November 10 at 1:57 PM
markets.businessinsider.com logoInovio Pharmaceuticals Inc. Q3 Earnings Summary
markets.businessinsider.com - November 10 at 8:42 AM
nasdaq.com logoNotable Tuesday Option Activity: INO, CRWD, THC
nasdaq.com - November 9 at 7:42 PM
nasdaq.com logoInovio Pharmaceuticals (INO) Reports Q3 Loss, Tops Revenue Estimates
nasdaq.com - November 9 at 7:42 PM
msn.com logoWhy Shares of Inovio Pharmaceuticals Rallied Today
msn.com - November 9 at 7:42 PM
markets.businessinsider.com logoInovio Pharmaceuticals Sees A Bounce Off Support After COVID-19 Vaccine News
markets.businessinsider.com - November 9 at 7:42 PM
finance.yahoo.com logoFDA Lifts Clinical Hold On Inovio's COVID-19 Vaccine Trial
finance.yahoo.com - November 9 at 2:42 PM
finance.yahoo.com logoInovio shares rise after FDA OK to complete testing of its Covid-19 vaccine candidate
finance.yahoo.com - November 9 at 2:42 PM
markets.businessinsider.com logoWhy INOVIO Is Rising In Pre-market?
markets.businessinsider.com - November 9 at 9:41 AM
finance.yahoo.com logoINOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
finance.yahoo.com - November 9 at 9:41 AM
finance.yahoo.com logoUPDATE 2-U.S. FDA lifts clinical hold on Inovio's COVID-19 vaccine trial
finance.yahoo.com - November 9 at 9:41 AM
finance.yahoo.com logoInovio says the FDA lifted its 'hold' on the Phase 3 clinical trial for its COVID-19 shot
finance.yahoo.com - November 9 at 9:41 AM
markets.businessinsider.com logoHere's what Wall Street expects from Inovio Pharmaceuticals's earnings report
markets.businessinsider.com - November 8 at 6:19 PM
finance.yahoo.com logoINOVIO Expands Executive Leadership to Prepare for Commercial Operations
finance.yahoo.com - November 5 at 8:19 AM
nasdaq.com logoInovio Gets Authorization For Phase 3 Trial Of INO-4800 COVID -19 Vaccine Candidate In India
nasdaq.com - November 3 at 9:11 AM
finance.yahoo.com logoINOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
finance.yahoo.com - November 3 at 9:10 AM
msn.com logoBRIEF-Inovio Pharmaceuticals Inc - On October 28, 2021, Medimmune Limited Provided Notice To Co To Terminate Ino-3112 / Medi0457 Development Program
msn.com - October 29 at 9:25 PM
finance.yahoo.com logoINOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021
finance.yahoo.com - October 27 at 8:26 AM
finance.yahoo.com logoINOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
finance.yahoo.com - October 26 at 10:27 AM
finance.yahoo.com logoINOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
finance.yahoo.com - October 21 at 8:25 AM
finance.yahoo.com logoBreakeven On The Horizon For Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
finance.yahoo.com - October 20 at 10:21 AM
nasdaq.com logoThose who invested in Inovio Pharmaceuticals (NASDAQ:INO) three years ago are up 37%
nasdaq.com - October 20 at 10:21 AM
markets.businessinsider.com logoINOVIO Reports Homologous Boosting Data For COVID-19 Vaccine Candidate - Quick Facts
markets.businessinsider.com - October 12 at 12:29 PM
finance.yahoo.com logoINOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
finance.yahoo.com - October 12 at 12:29 PM
finance.yahoo.com logoINOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
finance.yahoo.com - October 11 at 9:42 AM
nasdaq.com logoInteresting INO Put And Call Options For November 26th
nasdaq.com - October 7 at 5:00 PM
msn.com logoSan Diego pharmaceutical company beginning third phase of trials for new COVID-19 vaccine
msn.com - October 7 at 1:54 AM
finanznachrichten.de logoUSA News Group: New Covid-19 Vaccines Continue to Be Developed by Biotech Firms Seeking to Improve the Jab
finanznachrichten.de - October 6 at 12:20 PM
fool.com logoIs This The Turning Point for Inovio?
fool.com - October 6 at 12:20 PM
nasdaq.com logoInovio Pharmaceuticals Becomes Oversold (INO)
nasdaq.com - October 1 at 7:24 PM
marketwatch.com logoInovio Pharmaceuticals Inc. stock falls Wednesday, underperforms market
marketwatch.com - September 30 at 1:10 AM
nasdaq.com logoFirst Week of INO May 2022 Options Trading
nasdaq.com - September 27 at 3:17 PM
finance.yahoo.com logoIs Inovio Stock A Buy As It Moves Into Late-Stage Covid Vaccine Testing?
finance.yahoo.com - September 24 at 1:27 PM
Get Inovio Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.